Evaluation of some toxic effects of the glycoside convicine on albino rat

Isouramil [IU] is a glycone of the glycoside convicine isolated from faba beans [Vacia faba L.]. Convicine caused haemolytic crisis called Favism especially in patients deficient in glucose-6-phosphate dehydrogenase. In the present study the experiments were performed to investigate the convicine effect on albino rats. Three groups of albino rats were used. The first group was kept as a control, the second and third group were given oral dose of convicine [2 mg/100g b.wt.] for 15 and 30 days, respectively. The results revealed that convicine caused significant decrease [P < 0.05] in red blood cells. R.B.Cs and hemoglobin content. The analysis of serum albumin/globulin ratio a showed significant decrease [P < 0.05]. There were significant increases [P < 0.05] in serum and tissue total protein, serum bilirubin, globulin and iron. The results showed that convicine when hydrolyzed to its haemoglobin aglycon isouramil caused the same signs similar in many respects to those observed in human metabolic disease [Favism]

Reactions of uridine and 4-thiouridine derivatives with some-halo esters

Uridine and 4-thiouridine were converted into the corresponding 2,3-o-isopropylidene-5-thiocyanato derivatives. Then, each resulted derivative was reacted individually with both of ethyl alpha- chloroacetoacetate, ethyl alpha-bromobenzoylacetate and ethyl bromo pyruvate. Furthermore, these 5-thiocyanato products were transformed into the corresponding 5-mercapto analogues. The produced analogues were undergo ring formation to give the corresponding 4,5-cyclized pyrimidine derivatives

Synthesis of some uridine and cytidine derivatives

Some modified nucleosides were prepared from 5,6-disubstituted uridine, 5-substituted cytidine and cytidine. Different nucleophilic substitution reactions were carried out in alkaline or neutral medium. Some of these reactions describe ring formation

Cycloaddition reactions with both of uridine and 2-thiouridine derivatives

The present paper described work directed towards reactions of both of 2',3',5'-tri-O-acetyl uridine and its 2-thioanlogue with either of 2H- pyran-2-one, 4,6-dimethyl-2H-pyran-2-one and 2,3-bis [dibromomethyl] benzene to afford cycloaddition products

Estudio fase II de la administración secuencial de zidovudina (AZT), zalcitabina (ddC) y didanosina (ddI) a pacientes con infección avanzada por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) / Study of administration consecutive periods of zidorudine (AZT), zalcitabine (ddC) and didanosine (ddI) infected individuals by HIV-1

Se estudiaron prospectivamente 18 pacientes infectados por VIH-1 y tratados con AZT (100 mg. tid durante 30 días), alternando con ddC (0.375 mg. tid durante 30 días) y con ddl (100 mg. tid durante 30 días) por periódos de 12 a 28 semanas, media 20. Doce pacientes recibieron este tratamiento después de otros antirretrovirales y 6 lo recibieron desde el diagnóstico. Antes y después de AZT/ddC/ddI, la media de células CD4 cambió de 211 a 256/ul (p=.06), y la media de peso de 68.2 a 67.4 kg. (p=.05). Las cifras de hemoglobina se incrementaron significativamente de 14.8 a 15.4 gr/dl (p=.02); este efecto fue más notable en pacientes previamente expuestos a AZT. En 6 de 12 casos desapareció la antigenemia p24 y en 2 de 5 disminuyeron los niveles de beta2-microglobulina sérica. En ningún paciente hubo hiperamilasemia como efecto adverso del ddl y en uno se instaló neuropatía periférica sensorial reversible como efecto colateral de ddC; en seis que habían recibido AZT cesaron los efectos adversos como intolerancia gástrica, cefalea y fiebre. La administración combinada secuencial de AZT/ddC/ddl fue bien tolerada y disminuyó la toxicidad de AZT